C07K 14/8107
Endopeptidase inhibitors
Official title: {Endopeptidase (E.C. 3.4.21-99) inhibitors}
C07K14/8107 (Endopeptidase inhibitors) appears on 1,471 US grants and 1,642 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,471
- Published applications
- 1,642
- Assignees
- 891
- Inventors
- 3,499
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 3 | 0 |
| 1978 | 3 | 0 |
| 1979 | 3 | 0 |
| 1980 | 2 | 0 |
| 1981 | 3 | 0 |
| 1982 | 2 | 0 |
| 1983 | 3 | 0 |
| 1984 | 7 | 0 |
| 1985 | 3 | 0 |
| 1986 | 4 | 0 |
| 1987 | 4 | 0 |
| 1988 | 9 | 0 |
| 1989 | 9 | 0 |
| 1990 | 11 | 0 |
| 1991 | 12 | 0 |
| 1992 | 24 | 0 |
| 1993 | 30 | 0 |
| 1994 | 27 | 0 |
| 1995 | 34 | 0 |
| 1996 | 38 | 0 |
| 1997 | 53 | 0 |
| 1998 | 64 | 0 |
| 1999 | 78 | 0 |
| 2000 | 52 | 0 |
| 2001 | 56 | 11 |
| 2002 | 47 | 104 |
| 2003 | 51 | 158 |
| 2004 | 33 | 82 |
| 2005 | 48 | 82 |
| 2006 | 62 | 62 |
| 2007 | 51 | 60 |
| 2008 | 26 | 45 |
| 2009 | 26 | 54 |
| 2010 | 30 | 53 |
| 2011 | 24 | 54 |
| 2012 | 28 | 47 |
| 2013 | 30 | 48 |
| 2014 | 34 | 61 |
| 2015 | 41 | 57 |
| 2016 | 42 | 57 |
| 2017 | 39 | 80 |
| 2018 | 41 | 40 |
| 2019 | 51 | 51 |
| 2020 | 39 | 72 |
| 2021 | 41 | 74 |
| 2022 | 32 | 76 |
| 2023 | 29 | 59 |
| 2024 | 35 | 74 |
| 2025 | 37 | 48 |
| 2026 | 18 | 33 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Neutrophil elastase binding peptides and compositions thereof29 Sep 2026US 12,747,280 B2Case Western Reserve University
- Expression of the human lekti gene from the chromosome of Staphylococcus epidermidis29 Sep 2026US 12,747,281 B2Azitra Inc
- Ulinastatin polypeptides8 Sep 2026US 12,729,233 B2DiaMedica USA Inc.
- Vectors encoding a glucose-6-phosphatase (G6PASE-A) for gene therapy1 Sep 2026US 12,723,263 B2Genethon
- Application of MmPI in preparation of trypsin inhibitors30 Jun 2026US 12,668,618 B2Shaanxi University of Technology
- Methods and materials for treating gastrointestinal disorders27 Aug 2026US 2026/0248863 A1Mayo Foundation for Medical Education and Research
- Serine proteinase inhibitors: serp-1 and serp-1 rcl-derived peptides effect on microbiome composition and uses thereof27 Aug 2026US 2026/0248876 A1Arizona Board of Regents on behalf of Arizona State University
- Gene-edited natural killer cells27 Aug 2026US 2026/0250634 A1Crispr Therapeutics AG
- Compositions and methods for prevention and treatment of genetic disease20 Aug 2026US 2026/0240889 A1Children's Medical Center Corporation
- Therapeutic targeting of tumor escape by car-mediated trogocytosis20 Aug 2026US 2026/0241002 A1University of Maryland, Baltimore
Most cited
By later US patents
- Directed evolution of novel binding proteins2,450US 5,223,409 AProtein Engineering Corporation · 1993
- Viruses expressing chimeric binding proteins1,136US 5,403,484 AProtein Engineering Corporation · 1995
- Directed evolution of novel binding proteins1,057US 5,571,698 AProtein Engineering Corporation · 1996
- Anti-angiogenic compositions and methods of use968US 5,716,981 AAngiogenesis Technologies, Inc. · 1998
- Anti-angiogenic compositions and methods of use413US 5,886,026 AAngiotech Pharmaceuticals, Inc. · 1999